Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF August 23, 2019 | Archived Issues

Meetings and Events


Grand Rounds


Upcoming CME Conferences


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue.

Submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

FDA Finds No Increased Risk of Prostate Cancer With Parkinson's Medicines

The U.S. Food and Drug Administration (FDA) has found no increased risk of prostate cancer with Parkinson's disease medicines, Comtan (entacapone) and Stalevo (a combination of entacapone, carbidopa, and levodopa). The FDA alerted the public of a clinical trial in March 2010 suggesting a possible increased risk of prostate cancer with the entacapone component of Stalevo. But based on additional studies, the FDA has concluded that entacapone use is not associated with an increased risk of prostate cancer.

The FDA website has more information.